Darpan News Desk The Canadian Press, 01 Mar, 2022 10:51 AM
OTTAWA — The Canadian representative for the United Nations refugee agency, the UNHCR, says it's too early to begin to resettle Ukrainian refugees who have fled Russian aggression in their country by the thousands.
Rema Jamous says the scale of displacement from Ukraine is daunting, as some 500,000 people have already fled to neighbouring countries seeking safety.
If trends continue, the UNHCR estimates there could be as many as four million Ukrainian refugees.
Still, Jamous says most people who left Ukraine hope to return home when it is safe to do so.
In the meantime, she says, refugees inside and outside of Ukraine's borders will need humanitarian support, as current resources are likely to be depleted quickly.
The UNHCR will discuss resettlement options with countries like Canada at a later stage, but Jamous says typically the demand from people looking for a new home far outstrips the opportunities offered by governments.
If elected, Biden said, he would impose stiff new tax penalties on companies that manufacture U.S.-bound products outside the country, create incentives for keeping jobs on U.S. soil and close what he called "Trump loopholes" that allow companies engaged in offshoring to avoid paying U.S. taxes.
A spokesperson for AstraZeneca, via a statement said that the company’s “standard review process triggered a pause to vaccination to allow review of safety data.”
Prosecutors, defence lawyers and District Judge Theodore Chuang gathered today via conference call to set deadlines for the government's response to the motions and to set a hearing date.
Thursday’s report comes nearly two years after a Chinese scientist shocked the world by revealing he’d helped make the first gene-edited babies using a tool called CRISPR, which enables DNA changes or “edits” that can pass to future generations.
In an online forum today hosted by the Washington International Trade Association, DeFrancesco squared off against critics of the decision, including leading industry groups in both Canada and the U.S.
.jpg "AstraZeneca vaccine trial not going ahead due to adverse reaction in a subject")
